Please assess the completion status of the following clinical trial:

Trial Title: Observation Versus Occlusion Therapy for Intermittent Exotropia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12 months to \< 11 years~* Intermittent exotropia (manifest deviation) meeting all of the following criteria:~  * Intermittent exotropia at distance OR constant exotropia at distance and either intermittent exotropia or exophoria at near~ * Exodeviation at least 15PD at distance OR near measured by prism and alternate cover test (PACT)~ * Exodeviation at least 10PD at distance measured by PACT~* No previous surgical or non-surgical treatment for IXT (other than refractive correction)~* Visual acuity in the worse eye at least 0.3 logMAR (20/40 on ATS HOTV or 70 letters on E-ETDRS) for children ≥ 3 years of age~* No interocular difference of visual acuity more than 0.2 logMAR (2 lines on ATS HOTV or 10 letters on E-ETDRS) for children ≥ 3 years of age~* No hyperopia greater than +3.50 D spherical equivalent in either eye~* No myopia greater than -6.00 D spherical equivalent in either eye~* No prior strabismus, intraocular, or refractive surgery~* No abnormality of the cornea, lens, or central retina~* Investigator willing to observe the IXT untreated for 3 years unless specific criteria for deterioration are met~Exclusion Criteria:~* Pure phoria at both distance and near~* Prior non-surgical treatment for IXT other than refractive correction (e.g., vergence therapy, occlusion, vision therapy/orthoptics, or deliberate over-minus with spectacles more than 0.50D)~* Previous amblyopia treatment other than refractive correction within 1 year~* Vision therapy/orthoptics for any reason within the last year~* Interocular visual acuity difference more than 0.2 logMAR (2 lines on ATS HOTV for patients 3 to \< 7 years old or 10 letters on E-ETDRS for patients ≥ 7 years old) (patients ≥ 3 years only) and/or investigator plans to initiate amblyopia treatment at this time.~* Limitation of ocular rotations due to restrictive or paretic strabismus~* Craniofacial malformations affecting the orbits~* Ocular disorders which would reduce visual acuity (except refractive error)~* Prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery~* Strabismus surgery planned~* Known skin reactions to patch or bandage adhesives~* Significant neurological impairment such as cerebral palsy. Patients with mild speech delays or common reading and/or learning disabilities are not excluded.~* Investigator planning to change refractive correction at this time (if the patient is otherwise eligible, the investigator should consider prescribing refractive correction and bringing the patient back at a later time for enrollment)

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Patients randomized to the observation group will receive no treatment (other than refractive correction).
- Occlusion Therapy (Type: ACTIVE_COMPARATOR): Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).